Chlorambucil: Clinical Trials

54 trials of Chlorambucil, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

28 completed, 12 unknown, 8 terminated, 5 active not recruiting. 31 Phase 3, 14 Phase 2, 5 Phase 1, 3 Phase 4, 2 Not applicable.

By phase and status

Phase	Trials	Status
Phase 3	31	Completed 15, Unknown 8, Active not recruiting 4, Terminated 3, Recruiting 1
Phase 2	14	Completed 8, Terminated 3, Unknown 2, Active not recruiting 1
Phase 1	5	Terminated 3, Completed 2
Phase 4	3	Completed 2, Terminated 1
Not applicable	2	Unknown 2

Follow Chlorambucil: new trials by email Literature Review of Chlorambucil trials Research Report on Chlorambucil

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors BGB-16673, Bendamustine, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Active not recruiting	BeOne Medicines	153	2025-05-29	2026-08-24
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine - CLL/SLL	Phase 3	Recruiting	Ascentage Pharma Group Inc.	344	2024-04-07	2026-07-28
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL ICP-022, Chlorambucil, Rituximab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Unknown	Beijing InnoCare Pharma Tech Co., Ltd.	218	2021-01-08	2023-06-05
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) Chlorambucil, Oral, 2 Mg - Pancreatic Ductal Adenocarcinoma	Phase 2	Unknown	Michele Reni	20	2020-12-18	2023-09-21
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia Acalabrutinib, Rituximab, Chlorambucil - Untreated Chronic Lymphocytic Leukemia	Phase 3	Active not recruiting	AstraZeneca	155	2020-01-20	2026-09-14
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Ibrutinib, Venetoclax, Chlorambucil - Leukemia, Lymphocytic, Chronic, B-Cell	Phase 3	Active not recruiting	Janssen Research & Development, LLC	211	2018-04-17	2026-09-28
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities Chlorambucil, Obinutuzumab - Chronic Lymphocytic Leukemia		Completed	Hoffmann-La Roche	50	2016-11-23	2022-06-28
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia Obinutuzumab, Ublituximab, TGR-1202 - Chronic Lymphocytic Leukemia	Phase 3	Terminated	TG Therapeutics, Inc.	603	2015-11-19	2024-12-13
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities Chlorambucil, Obinutuzumab, Placebo - B-Cell Chronic Lymphocytic Leukemia	Phase 1	Terminated	Hoffmann-La Roche	38	2015-06-26	2021-04-08
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL Acalabrutinib, Obinutuzumab, Chlorambucil - Chronic Lymphocytic Leukemia	Phase 3	Active not recruiting	Acerta Pharma BV	535	2015-06-26	2026-08-25
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia Idelalisib, Chlorambucil, Obinutuzumab - Chronic Lymphocytic Leukemia	Phase 3	Terminated	Gilead Sciences	57	2015-04-21	2018-11-19
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia Chlorambucil, Venetoclax, Obinutuzumab - Lymphocytic Leukemia, Chronic	Phase 3	Completed	Hoffmann-La Roche	445	2014-12-31	2025-11-06
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Ibrutinib, Obinutuzumab, Chlorambucil - Chronic Lymphocytic Leukemia, Small-Cell Lymphoma	Phase 3	Completed	Pharmacyclics LLC.	229	2014-10-06	2020-09-21
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) TGR-1202 + Obinutuzumab + Chlorambucil - Chronic Lymphocytic Leukemia	Phase 1	Completed	TG Therapeutics, Inc.	19	2014-03-12	2019-10-02
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma Chlorambucil, Rituximab i.v., Rituximab s.c. - MALT Lymphoma	Phase 2	Active not recruiting	International Extranodal Lymphoma Study Group (IELSG)	112	2013-12-01	2026-01-15
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia Bendamustine, Chlorambucil, Cyclophosphamide - Chronic Lymphocytic Leukemia	Phase 3	Completed	Hoffmann-La Roche	979	2013-11-04	2019-10-28
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia Obinutuzumab, Chlorambucil - Chronic Lymphocytic Leukemia	Phase 2	Completed	Genentech, Inc.	20	2013-08-01	2017-04-17
A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia chlorambucil, tablets - Leukaemia, Lymphoblastic	Phase 2	Completed	GlaxoSmithKline	5	2013-04-01	2015-06-22
Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL Ibrutinib, Chlorambucil - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Completed	Pharmacyclics LLC.	269	2013-03-01	2017-11-30
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia chlorambucil, tablets, ofatumumab (GSK1841157) infusion - Leukaemia, Lymphocytic, Chronic	Phase 2	Completed	GlaxoSmithKline	10	2012-04-01	2015-08-10

Showing 20 of 54. Sign in to see all of them.

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (34) · Lymphoma (9) · Leukemia (6) · Lymphoma, B-Cell, Marginal Zone (5) · Leukemia, B-Cell (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Recurrence (3) · Neoplasms (2) · Waldenstrom Macroglobulinemia (2) · Glomerulonephritis, Membranous (1) · Glomerulosclerosis, Focal Segmental (1) · Hodgkin Disease (1) · Stomach Neoplasms (1) · Uveitis (1)

Countries

United Kingdom (27) · Italy (20) · France (19) · Spain (17) · United States (16) · Russia (14) · Canada (13) · Poland (13) · Belgium (12) · Australia (11) · Czechia (10) · Germany (10) · Israel (9) · Netherlands (9) · New Zealand (9)

Top investigators

Barry W. Hancock, MD (2) · Emanuele Zucca, MD (2) · John Martin, MD (2) · A. Barratt, MD (1) · Andy Haynes, MD (1) · Ann Barrett (1) · Branimir Jaksic, MD, PhD (1) · Catherine Thieblemont, MD (1) · Daniel Catovsky, MD (1) · Daniel TM Chan, Prof (1) · Douglas Jabs, MD, MBA (1)

Results publications

PMID 23065509, PMID 23233721, PMID 34865212, PMID 35014928, PMID 38620092, PMID 40266025, PMID 11895791, PMID 12756499, PMID 16314615, PMID 17658394, PMID 19016733, PMID 19036078, PMID 19605849, PMID 20220059, PMID 20511662, PMID 21483000, PMID 21652026, PMID 21659360, PMID 21816833, PMID 21840602, PMID 21861971, PMID 22168274, PMID 22247489, PMID 22409563, PMID 23091097, PMID 23163490, PMID 23295789, PMID 24401022, PMID 24638012, PMID 25103870, PMID 25115882, PMID 25882396, PMID 26501236, PMID 26639149, PMID 26798977, PMID 28140392, PMID 28477440, PMID 28751558, PMID 28771673, PMID 29255066, PMID 29296805, PMID 29749403, PMID 29880603, PMID 30522969, PMID 31050355, PMID 31166681, PMID 31196847, PMID 31455851, PMID 31723767, PMID 32305093

NIH funding

2009 (4), 2014 (3), 2008 (2), 2015 (1), 2017 (1), 2023 (1), U10EY014660 (1)